Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient...

Area of Science:

• Biomedical science
• Cardiovascular research
• Molecular genetics

Background:

• Vascular spasm acutely reduces blood supply and tissue oxygenation.
• Sarcoglycan gene mutations in mice cause cardiomyopathy with focal damage.
• Vascular spasm was hypothesized to cause focal necrosis in sarcoglycan-deficient hearts.

Purpose of the Study:

• To investigate the role of vascular spasm in sarcoglycan-null cardiomyopathy.
• To determine if sarcoglycan expression in cardiomyocytes or vascular smooth muscle corrects the phenotype.

Main Methods:

• Utilized a transgene rescue strategy in sarcoglycan-null mice.
• Restored sarcoglycan expression specifically in cardiomyocytes.
• Restored sarcoglycan expression in vascular smooth muscle.
• Administered nitric oxide synthase inhibitors.

Main Results:

• Cardiomyocyte-specific sarcoglycan expression corrected cardiac focal degeneration.
• Restoration of cardiomyocyte sarcoglycan also eliminated coronary artery vascular spasm.
• Smooth muscle sarcoglycan restoration did not correct the cardiac phenotype or vascular spasm.
• Nitric oxide synthase inhibitors partially corrected the tissue damage-induced vascular spasm.

Conclusions:

• Tissue damage, potentially via cytokine release from cardiomyocytes, can induce vascular spasm.
• Vascular spasm exacerbates cardiac damage in a feedback loop.
• Targeting cardiomyocyte sarcoglycan is crucial for preventing vascular spasm and cardiac damage.